Selective utilization of circulating tumor DNA testing enables disease monitoring in endometrial and ovarian carcinomas.

ctDNA can reflect larger tumor volume/metastases, treatment response and recurrence in EC and OC. Careful patient selection is critical to direct resources to patients most likely to benefit, considering disease burden and risk group.